Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7717526 | 1.00 | KIF11 (0.49) | KIF11RAB9ASMN1; SMN2HPGDMEN1 | |
| SCHEMBL8758435 | 1.00 | KIF11 (0.49) | KIF11RAB9ASMN1; SMN2HPGDMEN1 | |
| SCHEMBL239300 | 0.84 | MAPT (0.47) | RAB9AMEN1KMT2ACYP2C9NPC1 | |
| SCHEMBL239301 | 0.84 | MAPT (0.47) | RAB9AMEN1KMT2ACYP2C9NPC1 | |
| SCHEMBL1421530 | 0.84 | MEN1 (0.57) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL2282234 | 0.84 | MEN1 (0.57) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL669319 | 0.84 | MEN1 (0.57) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| Water SCHEMBL9435219 | 0.82 | MAPT (0.45) | RAB9AMEN1KMT2ACYP2C9NPC1 | |
| SCHEMBL7028109 | 0.82 | CA12 (0.47) | RAB9AHPGDMEN1KMT2AHIF1A | |
| SCHEMBL7089012 | 0.82 | CA12 (0.47) | RAB9AHPGDMEN1KMT2AHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334313-B2 | Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2012-12-18 | — | — | US | disclosed |
| EP-1542667-B1 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20110130391-A1 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. | 2011-06-02 | — | — | US | disclosed |
| US-7902241-B2 | 3-[3-(4-ISOPROPYLPHENYL)-2,5-DIOXO-IMIDAZOLIDIN-1-YL]- or 2-OXO-2,3-DIHYDROIMIDAZOL-1-YL]BENZOIC ACID; modulating premature translation termination and nonsense-mediated mRNA decay; gene therapy; cystic fibrosis or Duchenne muscular dystrophy; cancer, autoimmune disease, blood disease, diabetes | PTC THERAPEUTICS, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080275233-A1 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. | 2008-11-06 | — | — | US | disclosed |
| US-7405233-B2 | Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20060167065-A1 | Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. | 2006-07-27 | — | — | US | disclosed |
| EP-1542667-A2 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004009558-A2 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS, THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASES CAUSED BY SUCH MUTATIONS | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| US-6384014-B1 | ANTIBIOTICS AS BACTERICIDES | AVENTIS PHARMA S.A. (FR) | 2002-05-07 | — | — | US | disclosed |
| EP-0773956-A1 | PURIFIED FORM OF STREPTOGRAMINES, PREPARATION OF SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996004298-A1 | PURIFIED FORM OF STREPTOGRAMINES, PREPARATION OF SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | RHONE-POULENC RORER S.A. (FR) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167065-A1 | Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease | UPF1, VHL, URB2 | KIF11 4356/4885RAB9A 3148/4885SMN1; SMN2 166/4885 |
| US-20110130391-A1 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | UPF1, VHL, URB2 | KIF11 4356/4885RAB9A 3148/4885SMN1; SMN2 166/4885 |
| US-20080275233-A1 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | UPF1, VHL, URB2 | KIF11 4356/4885RAB9A 3148/4885SMN1; SMN2 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.